Interleukin-7 (IL7) is a cytokine that controls the proliferation, apoptosis and activation of CD4 and CD8 effector T-cells in humans.
OSE-127, a humanized monoclonal antibody, is an antagonist of the IL7 receptor (IL7R) present on T effector cells, the CD127 receptor, thus down regulating the immune activity.
OSE-127 is under an option license agreement signed with Servier in December 2016 to be developed up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease; in parallel, OSE-127 will be developed in Sjögren’s syndrome, the second most frequent auto-immune disease.
ABOUT THE OSE-127 CLINICAL PROGRAM
OSE-127 is currently under a first-in-human dose-escalation, randomized, double-blind, placebo-controlled Phase 1 clinical trial.
This study aims to evaluate the safety and tolerability of single- and multiple-ascending intravenous and subcutaneous doses of OSE-127 in 63 healthy volunteers. Secondary endpoints include measures of pharmacokinetics, pharmacodynamics and immunogenicity to help assess and understand how the drug is absorbed and metabolized. In addition, exploratory biomarkers will be used to assess OSE-127’s potential for the treatment of inflammatory autoimmune diseases.